This subproject is one of many research subprojects utilizing theresources provided by a Center grant funded by NIH/NCRR. The subproject andinvestigator (PI) may have received primary funding from another NIH source,and thus could be represented in other CRISP entries. The institution listed isfor the Center, which is not necessarily the institution for the investigator.To examine whether standardized extracts of Ginko biloba (Gb) might be a useful added agent in treating symptoms of schizophrenia, particularly negative symptoms and/or improve their brain function and memory. The study will use a double-blind, randomized, placebo-controlled design, and will include 100 subjects with treatment resistant schizophrenia. Subjects will be randomized to receive either a standard dose of Gb or placebo for 12 weeks in addition to continuing their treatment with anti psychotic medications that have been judged as optimal prior to entering the study. Standard assessment instruments will be used for measuring changes in symptoms (both positive and negative), neurocognitive performance and functioning status. Assessments will be done at baseline, and at the end of weeks 2,4,6 and 12.
Showing the most recent 10 out of 1232 publications
